

Samuel C Mok

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/963287/publications.pdf>

Version: 2024-02-01

161
papers

12,490
citations

20817

60
h-index

26613

107
g-index

166
all docs

166
docs citations

166
times ranked

15426
citing authors

#	ARTICLE	IF	CITATIONS
1	Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer. <i>New England Journal of Medicine</i> , 2008, 359, 2641-2650.	27.0	633
2	Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. <i>Nature Communications</i> , 2016, 7, 11150.	12.8	577
3	Disruption of the Fanconi anemiaâ€“BRCA pathway in cisplatin-sensitive ovarian tumors. <i>Nature Medicine</i> , 2003, 9, 568-574.	30.7	508
4	Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas. <i>Cancer Research</i> , 2005, 65, 2162-2169.	0.9	484
5	Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 1671.	7.4	391
6	Potential markers that complement expression of CA125 in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 99, 267-277.	1.4	324
7	TGF-Î² Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment. <i>Cancer Research</i> , 2013, 73, 5016-5028.	0.9	315
8	Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary. <i>Cancer Research</i> , 2005, 65, 10602-10612.	0.9	298
9	Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. <i>Cell Metabolism</i> , 2016, 24, 685-700.	16.2	293
10	BRCA1 Supports XIST RNA Concentration on the Inactive X Chromosome. <i>Cell</i> , 2002, 111, 393-405.	28.9	283
11	Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. <i>American Journal of Physiology - Cell Physiology</i> , 2015, 309, C444-C456.	4.6	272
12	Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology. <i>Journal of the National Cancer Institute</i> , 2001, 93, 1458-1464.	6.3	268
13	A Gene Signature Predictive for Outcome in Advanced Ovarian Cancer Identifies a Survival Factor: Microfibril-Associated Glycoprotein 2. <i>Cancer Cell</i> , 2009, 16, 521-532.	16.8	230
14	Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. <i>Clinical Cancer Research</i> , 2003, 9, 2904-11.	7.0	208
15	SPARC (Secreted Protein Acidic and Rich in Cysteine) Induces Apoptosis in Ovarian Cancer Cells. <i>American Journal of Pathology</i> , 2001, 159, 609-622.	3.8	199
16	Characterization of Human Ovarian Surface Epithelial Cells Immortalized by Human Papilloma Viral Oncogenes (HPV-E6E7 ORFs). <i>Experimental Cell Research</i> , 1995, 218, 499-507.	2.6	191
17	BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas. <i>American Journal of Pathology</i> , 2010, 177, 1611-1617.	3.8	183
18	Molecular Cloning of Differentially Expressed Genes in Human Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1994, 52, 247-252.	1.4	166

#	ARTICLE	IF	CITATIONS
19	Bcl-2 and p53 Protein Expression, Apoptosis, and p53 Mutation in Human Epithelial Ovarian Cancers. <i>American Journal of Pathology</i> , 2000, 156, 409-417.	3.8	152
20	Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. <i>International Journal of Cancer</i> , 2009, 124, 1358-1365.	5.1	148
21	Proteomic-Based Discovery and Characterization of Glycosylated Eosinophil-Derived Neurotoxin and COOH-Terminal Osteopontin Fragments for Ovarian Cancer in Urine. <i>Clinical Cancer Research</i> , 2006, 12, 432-441.	7.0	147
22	Cancer-Associated Fibroblasts and Their Putative Role in Potentiating the Initiation and Development of Epithelial Ovarian Cancer. <i>Neoplasia</i> , 2011, 13, 393-405.	5.3	136
23	Hypoxia Enhances Lysophosphatidic Acid Responsiveness in Ovarian Cancer Cells and Lysophosphatidic Acid Induces Ovarian Tumor Metastasis In vivo. <i>Cancer Research</i> , 2006, 66, 7983-7990.	0.9	132
24	Whole Genome Oligonucleotide-Based Array Comparative Genomic Hybridization Analysis Identified Fibroblast Growth Factor 1 As a Prognostic Marker for Advanced-Stage Serous Ovarian Adenocarcinomas. <i>Journal of Clinical Oncology</i> , 2007, 25, 2281-2287.	1.6	131
25	Reproductive Hormone-Induced, STAT3-Mediated Interleukin 6 Action in Normal and Malignant Human Ovarian Surface Epithelial Cells. <i>Journal of the National Cancer Institute</i> , 2002, 94, 617-629.	6.3	117
26	Lysophospholipids Increase Interleukin-8 Expression in Ovarian Cancer Cells. <i>Gynecologic Oncology</i> , 2001, 81, 291-300.	1.4	113
27	Increased HLA-DMB Expression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 7667-7673.	7.0	113
28	Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. <i>Nature Communications</i> , 2014, 5, 5092.	12.8	112
29	Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. <i>Journal of Clinical Investigation</i> , 2017, 128, 589-606.	8.2	105
30	DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. <i>Oncogene</i> , 1998, 17, 419-424.	5.9	99
31	Claudin-4 Overexpression in Epithelial Ovarian Cancer Is Associated with Hypomethylation and Is a Potential Target for Modulation of Tight Junction Barrier Function Using a C-Terminal Fragment of Clostridium perfringens Enterotoxin. <i>Neoplasia</i> , 2007, 9, 304-314.	5.3	98
32	Immune Microenvironment in Microsatellite-Unstable Endometrial Cancers: Hereditary or Sporadic Origin Matters. <i>Clinical Cancer Research</i> , 2017, 23, 4473-4481.	7.0	96
33	Human Omental-Derived Adipose Stem Cells Increase Ovarian Cancer Proliferation, Migration, and Chemoresistance. <i>PLoS ONE</i> , 2013, 8, e81859.	2.5	95
34	Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. <i>Clinical Cancer Research</i> , 2002, 8, 3324-31.	7.0	94
35	Relationship of XIST expression and responses of ovarian cancer to chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 769-76.	4.1	92
36	Selenium binding protein 1 in ovarian cancer. <i>International Journal of Cancer</i> , 2006, 118, 2433-2440.	5.1	90

#	ARTICLE	IF	CITATIONS
37	Expression Profiling Identifies Altered Expression of Genes That Contribute to the Inhibition of Transforming Growth Factor- β Signaling in Ovarian Cancer. <i>Cancer Research</i> , 2006, 66, 8404-8412.	0.9	90
38	Identification of a Potential Ovarian Cancer Stem Cell Gene Expression Profile from Advanced Stage Papillary Serous Ovarian Cancer. <i>PLoS ONE</i> , 2012, 7, e29079.	2.5	87
39	Identification of Differentially Expressed Genes from Ovarian Cancer Cells by MICROMAX [®] , a cDNA Microarray System. <i>BioTechniques</i> , 2001, 30, 670-675.	1.8	85
40	Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 3474-3478.	7.0	85
41	The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With Differentiation and Survival in Ovarian Cancer. <i>American Journal of Surgical Pathology</i> , 2011, 35, 904-912.	3.7	83
42	Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer. <i>Journal of Pathology</i> , 2017, 242, 140-151.	4.5	83
43	Prostate carcinoma tissue proteomics for biomarker discovery. <i>Cancer</i> , 2003, 98, 2576-2582.	4.1	82
44	ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. <i>Oncotarget</i> , 2017, 8, 16951-16963.	1.8	82
45	Aberrant Promoter Methylation of Sparc in Ovarian Cancer. <i>Neoplasia</i> , 2009, 11, 126-IN1.	5.3	81
46	Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array. <i>Human Genetics</i> , 2004, 115, 327-30.	3.8	79
47	Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 809-820.	7.0	78
48	PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. <i>Modern Pathology</i> , 2009, 22, 1243-1250.	5.5	76
49	FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 4435-4448.	8.2	76
50	Candidate Tumor-Suppressor Gene DLEC1 Is Frequently Downregulated by Promoter Hypermethylation and Histone Hypoacetylation in Human Epithelial Ovarian Cancer. <i>Neoplasia</i> , 2006, 8, 268-278.	5.3	75
51	PTEN expression in clear cell adenocarcinoma of the ovary. <i>Gynecologic Oncology</i> , 2006, 101, 71-75.	1.4	74
52	Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. <i>Clinical Cancer Research</i> , 2003, 9, 4811-8.	7.0	73
53	Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 119, 114-120.	1.4	71
54	Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers. <i>PLoS ONE</i> , 2011, 6, e21121.	2.5	71

#	ARTICLE	IF	CITATIONS
55	Identification of Overexpression and Amplification of ABCF2 in Clear Cell Ovarian Adenocarcinomas by cDNA Microarray Analyses. <i>Clinical Cancer Research</i> , 2005, 11, 6880-6888.	7.0	70
56	Activation of Platelet-Activating Factor Receptor and Pleiotropic Effects on Tyrosine Phospho-EGFR/Src/FAK/Paxillin in Ovarian Cancer. <i>Cancer Research</i> , 2008, 68, 5839-5848.	0.9	70
57	k-ras Mutation May Be an Early Event in Mucinous Ovarian Tumorigenesis. <i>International Journal of Gynecological Pathology</i> , 2001, 20, 244-251.	1.4	66
58	Expression Profiling of Mucinous Tumors of the Ovary Identifies Genes of Clinicopathologic Importance. <i>Clinical Cancer Research</i> , 2006, 12, 690-700.	7.0	64
59	Blood and Urine Markers for Ovarian Cancer: A Comprehensive Review. <i>Disease Markers</i> , 2004, 20, 53-70.	1.3	63
60	Expression of Epidermal Growth Factor Receptor-Related Family Products in Gestational Trophoblastic Diseases and Normal Placenta and Its Relationship with Development of Postmolar Tumor. <i>Gynecologic Oncology</i> , 2000, 77, 389-393.	1.4	62
61	Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. <i>Clinical Cancer Research</i> , 2003, 9, 4782-91.	7.0	61
62	Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. <i>Gynecologic Oncology</i> , 2005, 96, 77-83.	1.4	60
63	SPARC Inhibits LPA-Mediated Mesothelial- <i>in situ</i> Ovarian Cancer Cell Crosstalk. <i>Neoplasia</i> , 2007, 9, 23-35.	5.3	59
64	p53 Gene Mutation in Human Borderline Epithelial Ovarian Tumors. <i>Journal of the National Cancer Institute</i> , 1994, 86, 1549-1551.	6.3	58
65	Analysis of p73 in human borderline and invasive ovarian tumor. <i>Oncogene</i> , 2000, 19, 1885-1890.	5.9	58
66	Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. <i>Gynecologic Oncology</i> , 2007, 106, 311-317.	1.4	58
67	S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1993-2002.	4.1	57
68	Use of a Combination of Approaches to Identify and Validate Relevant Tumor-Associated Antigens and Their Corresponding Autoantibodies in Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2008, 14, 764-771.	7.0	57
69	Microscopic and Early-Stage Ovarian Cancers in <i>BRCA1/2</i> Mutation Carriers: Building a Model for Early BRCA-Associated Tumorigenesis. <i>Cancer Prevention Research</i> , 2011, 4, 463-470.	1.5	53
70	DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. <i>Oncogene</i> , 2001, 20, 6960-6964.	5.9	51
71	Clusterin Interacts with Paclitaxel and Confer Paclitaxel Resistance in Ovarian Cancer. <i>Neoplasia</i> , 2008, 10, 964-IN7.	5.3	50
72	Matrix Metalloproteinases and Their Inhibitors in Gestational Trophoblastic Diseases and Normal Placenta. <i>Gynecologic Oncology</i> , 1999, 75, 248-253.	1.4	49

#	ARTICLE	IF	CITATIONS
73	Differential Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Protein and mRNA in Epithelial Ovarian Tumors. <i>Gynecologic Oncology</i> , 2000, 77, 369-376.	1.4	49
74	Inflammatory Cytokine Tumor Necrosis Factor α Confers Precancerous Phenotype in an Organoid Model of Normal Human Ovarian Surface Epithelial Cells. <i>Neoplasia</i> , 2009, 11, 529-541.	5.3	48
75	RUNX3 protein is overexpressed in human epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 112, 325-330.	1.4	47
76	The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2011, 123, 13-18.	1.4	47
77	Down-Regulation of DOC-2 in Colorectal Cancer Points to Its Role as a Tumor Suppressor in This Malignancy. <i>Diseases of the Colon and Rectum</i> , 2002, 45, 1242-1248.	1.3	45
78	Protein profiling of complete mole and normal placenta using ProteinChip analysis on laser capture microdissected cells.††The authors have no connection to any companies or products mentioned in this article.. <i>Gynecologic Oncology</i> , 2003, 88, 424-428.	1.4	44
79	Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. <i>Proteomics</i> , 2005, 5, 3183-3192.	2.2	44
80	C Terminus of <i>Clostridium perfringens</i> Enterotoxin Downregulates CLDN4 and Sensitizes Ovarian Cancer Cells to Taxol and Carboplatin. <i>Clinical Cancer Research</i> , 2011, 17, 1065-1074.	7.0	44
81	A new human topoisomerase III that interacts with SGS1 protein. <i>Nucleic Acids Research</i> , 1999, 27, 993-1000.	14.5	43
82	New technologies for the identification of markers for early detection of ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2003, 15, 51-55.	2.0	43
83	Gene Expression Signature of Normal Cell-of-Origin Predicts Ovarian Tumor Outcomes. <i>PLoS ONE</i> , 2013, 8, e80314.	2.5	43
84	Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment. <i>Biomolecules</i> , 2016, 6, 3.	4.0	43
85	Etiology and Pathogenesis of Epithelial Ovarian Cancer. <i>Disease Markers</i> , 2007, 23, 367-376.	1.3	42
86	Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 272-282.	6.3	42
87	Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. <i>Molecular Carcinogenesis</i> , 2000, 28, 236-246.	2.7	41
88	Poor survival with wild-type TP53 ovarian cancer?. <i>Gynecologic Oncology</i> , 2013, 130, 565-569.	1.4	40
89	Overexpression of the Protein Tyrosine Phosphatase, Nonreceptor Type 6 (PTPN6), in Human Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1995, 57, 299-303.	1.4	39
90	Ovarian cancer is a heterogeneous disease. <i>Cancer Genetics and Cytogenetics</i> , 2005, 161, 170-173.	1.0	39

#	ARTICLE	IF	CITATIONS
91	Epigenetic Silencing of Cellular Retinol-Binding Proteins in Nasopharyngeal Carcinoma. <i>Neoplasia</i> , 2005, 7, 67-74.	5.3	39
92	Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6417-6428.	7.0	39
93	Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes. <i>Cancer Research</i> , 2002, 62, 6218-23.	0.9	39
94	Novel anti-filamin A antibody detects a secreted variant of filamin A in plasma from patients with breast carcinoma and high grade astrocytoma. <i>Cancer Science</i> , 2009, 100, 1748-1756.	3.9	38
95	Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. <i>JCI Insight</i> , 2017, 2, .	5.0	38
96	A novel 4â€‰cM minimal deletion unit on chromosome 6q25.1-q25.2 associated with high grade invasive epithelial ovarian carcinomas. <i>Oncogene</i> , 1998, 16, 555-559.	5.9	37
97	Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. <i>Oncotarget</i> , 2015, 6, 44551-44562.	1.8	37
98	Genetic Alterations of the WT1 Gene in Papillary Serous Carcinoma of the Peritoneum. <i>Gynecologic Oncology</i> , 2000, 76, 369-372.	1.4	36
99	Progress in concurrent analysis of loss of heterozygosity and comparative genomic hybridization utilizing high density single nucleotide polymorphism arrays. <i>Cancer Genetics and Cytogenetics</i> , 2005, 159, 53-57.	1.0	36
100	Molecular Characterization and Mapping of Murine Genes Encoding Three Members of the Stefin Family of Cysteine Proteinase Inhibitors. <i>Genomics</i> , 1993, 15, 507-514.	2.9	35
101	Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target. <i>Oncogene</i> , 1999, 18, 4640-4642.	5.9	34
102	The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 509-519.	2.5	34
103	Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis. <i>Scientific Reports</i> , 2017, 7, 10374.	3.3	33
104	Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. <i>Cancer Genetics and Cytogenetics</i> , 2004, 155, 97-107.	1.0	32
105	Differential Gene Expression Pattern between Normal Human Trophoblast and Choriocarcinoma Cell Lines: Downregulation of Heat Shock Protein-27 in Choriocarcinoma in Vitro and in Vivo. <i>Gynecologic Oncology</i> , 1999, 75, 391-396.	1.4	31
106	Whole genome loss of heterozygosity profiling on oral squamous cell carcinoma by high-density single nucleotide polymorphic allele (SNP) array. <i>Cancer Genetics and Cytogenetics</i> , 2004, 151, 82-84.	1.0	29
107	Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. <i>Cancer Research</i> , 2002, 62, 3058-62.	0.9	29
108	ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression. <i>Cancers</i> , 2018, 10, 464.	3.7	28

#	ARTICLE	IF	CITATIONS
109	ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment. <i>Nature Communications</i> , 2020, 11, 3546.	12.8	28
110	KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1. <i>Oncotarget</i> , 2015, 6, 31702-31720.	1.8	27
111	BRCA1 Gene Mutations in Women With Papillary Serous Carcinoma of the Peritoneum. <i>Obstetrics and Gynecology</i> , 1998, 92, 596-600.	2.4	26
112	DOC-2/hDab2 Expression Is Up-Regulated in Primary Pancreatic Cancer but Reduced in Metastasis. <i>Laboratory Investigation</i> , 2001, 81, 863-873.	3.7	26
113	PAX2 Expression in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 6090-6105.	4.1	26
114	CAF reprogramming inhibits ovarian cancer progression. <i>Cell Cycle</i> , 2014, 13, 3783-3784.	2.6	26
115	Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum. <i>Oncogene</i> , 1998, 16, 3455-3459.	5.9	25
116	Expression of long noncoding RNAs in cancer-associated fibroblasts linked to patient survival in ovarian cancer. <i>Cancer Science</i> , 2020, 111, 1805-1817.	3.9	25
117	Multicolor spectral karyotyping of serous ovarian adenocarcinoma. <i>Genes Chromosomes and Cancer</i> , 2002, 33, 123-132.	2.8	24
118	Clusterin confers paclitaxel resistance in cervical cancer. <i>Gynecologic Oncology</i> , 2006, 103, 996-1000.	1.4	24
119	Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision. <i>Cancers</i> , 2018, 10, 57.	3.7	24
120	Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression. <i>Cancers</i> , 2020, 12, 118.	3.7	22
121	Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53. <i>Cancer</i> , 2014, 120, 3457-3468.	4.1	21
122	Dynamic expression of Dab2 in the mouse embryonic central nervous system. <i>BMC Developmental Biology</i> , 2008, 8, 76.	2.1	20
123	Pathogenesis and Clinical Management of Uterine Serous Carcinoma. <i>Cancers</i> , 2020, 12, 686.	3.7	20
124	Whole-Genome Allelotyping Identified Distinct Loss-of-Heterozygosity Patterns in Mucinous Ovarian and Appendiceal Carcinomas. <i>Clinical Cancer Research</i> , 2005, 11, 7651-7657.	7.0	19
125	Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. <i>Expert Review of Proteomics</i> , 2007, 4, 121-131.	3.0	18
126	Immune cell profiling in normal pregnancy, partial and complete molar pregnancy. <i>Gynecologic Oncology</i> , 2007, 107, 292-297.	1.4	18

#	ARTICLE	IF	CITATIONS
127	Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. <i>Nature Communications</i> , 2019, 10, 4369.	12.8	18
128	A Population-Based Study of BRCA1 and BRCA2 Mutations in Jewish Women With Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 1999, 93, 34-37.	2.4	17
129	Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. <i>Gynecologic Oncology</i> , 2008, 109, 234-239.	1.4	16
130	Distinct Allelic Loss Patterns in Papillary Serous Carcinoma of the Peritoneum. <i>American Journal of Clinical Pathology</i> , 2000, 114, 93-99.	0.7	15
131	Osteopontin is down-regulated in hydatidiform mole. <i>Gynecologic Oncology</i> , 2003, 89, 134-139.	1.4	14
132	Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1515-1526.	4.2	14
133	Recent advances in molecular biology of gestational trophoblastic diseases. A review. <i>Journal of reproductive medicine, The</i> , 2002, 47, 369-79.	0.2	14
134	SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 1777.	3.7	13
135	Molecular biology of gestational trophoblastic neoplasia: a review. <i>Journal of reproductive medicine, The</i> , 2004, 49, 415-22.	0.2	13
136	Biomarker Discovery in Epithelial Ovarian Cancer by Genomic Approaches. <i>Advances in Cancer Research</i> , 2006, 96, 1-22.	5.0	12
137	Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors. <i>Oncogene</i> , 1999, 18, 257-262.	5.9	11
138	Comparison of Osteopontin Expression in Endometrioid Endometrial Cancer and Ovarian Endometrioid Cancer. <i>Medical Oncology</i> , 2006, 23, 205-212.	2.5	11
139	Monitoring of ovarian cancer cell invasion in real time with frequency-dependent impedance measurement. <i>American Journal of Physiology - Cell Physiology</i> , 2016, 311, C1040-C1047.	4.6	10
140	DNA copy number abnormality of oral squamous cell carcinoma detected with cDNA array-based comparative genomic hybridization. <i>Cancer Genetics and Cytogenetics</i> , 2004, 151, 90-92.	1.0	9
141	The Monkey, the Hen, and the Mouse: Models to Advance Ovarian Cancer Chemoprevention. <i>Cancer Prevention Research</i> , 2009, 2, 773-775.	1.5	9
142	Expression of cytokines and receptors in normal, immortalized, and malignant ovarian epithelial cell lines. <i>Anticancer Research</i> , 2003, 23, 3151-7.	1.1	9
143	Transcriptional analyses of the gene region that encodes human histidyl-tRNA synthetase: identification of a novel bidirectional regulatory element. <i>Gene</i> , 1993, 131, 201-208.	2.2	8
144	Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. <i>Cancers</i> , 2020, 12, 2436.	3.7	8

#	ARTICLE	IF	CITATIONS
145	Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1369-1378.	6.3	8
146	Overexpression of laminin receptor 1 on decidual cells in partial and complete mole. <i>Gynecologic Oncology</i> , 2008, 108, 121-125.	1.4	7
147	Vascularization and expression of angiogenic factors in partial and complete molar pregnancies. <i>Journal of reproductive medicine, The</i> , 2008, 53, 589-94.	0.2	7
148	Disabled-2: a positive regulator of the early differentiation of myoblasts. <i>Cell and Tissue Research</i> , 2020, 381, 493-508.	2.9	6
149	ras Gene Activation and Infrequent Mutation in Papillary Serous Carcinoma of the Peritoneum. <i>Gynecologic Oncology</i> , 2000, 77, 105-111.	1.4	4
150	Biomarkers of Mucinous Tumors of the Ovary. <i>Disease Markers</i> , 2007, 23, 389-396.	1.3	4
151	An image informatics pipeline for imaging mass cytometry to characterize the immune landscape in pre- and on-treatment immune therapy and its application in recurrent platinum-resistant epithelial ovarian cancer. , 2019, , .		2
152	Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. <i>Cancers</i> , 2021, 13, 3218.	3.7	2
153	Immune cell profiling in intraplacental and postmolar choriocarcinomas. <i>Journal of reproductive medicine, The</i> , 2008, 53, 558-64.	0.2	2
154	Inhibition of Dab2 Expression with Antisense Oligodeoxynucleotides in Mouse Embryos. <i>Neuroembryology and Aging</i> , 2008, 5, 89-99.	0.1	1
155	Expression of Dab2, a Tumor Suppressor, in the Human Fetal Hippocampus and Neocortex. <i>Neuroembryology and Aging</i> , 2008, 5, 182-190.	0.1	1
156	Clear cell ovarian tumors display a unique tumor immune microenvironment. <i>Gynecologic Oncology</i> , 2021, 162, S110-S111.	1.4	1
157	Pancreatic cancer-derived exosomes: new role in paraneoplastic syndromes?. <i>Translational Cancer Research</i> , 2016, 5, S697-S700.	1.0	1
158	Antigen-specific T cell immune response detected by skewed T cell receptor usage in normal placenta and complete molar pregnancy. <i>Journal of reproductive medicine, The</i> , 2008, 53, 528-34.	0.2	1
159	Letter from the New Editor-in-Chief. <i>Cancers</i> , 2016, 8, 9.	3.7	0
160	Involvement of Disabled-2 in early myogenesis. <i>FASEB Journal</i> , 2013, 27, 524.3.	0.5	0
161	Mobilization of Intracellular Calcium Stores and ER-Mitochondrial Coupling in High-Grade Serous Ovarian Cancer (HGSOC) Cells. <i>FASEB Journal</i> , 2019, 33, .	0.5	0